Seaport Therapeutics

ADVANCING THE DEVELOPMENT OF NOVEL MEDICINES FOR DEPRESSION, ANXIETY AND OTHER NEUROPSYCHIATRIC DISORDERS

Seaport Therapeutics uses Glyph™ a unique drug delivery platform based on technology originally developed by researchers at Monash University.

The Glyph platform, developed by Professor Christopher Porter and his team from the Monash Institute of Pharmaceutical Sciences (MIPS), is designed to enable and enhance oral bioavailability of clinically-active drugs that were previously hindered by limitations, including first-pass metabolism, liver enzyme elevations, hepatotoxicity, and other side-effects.

Since licensing the Glyph technology, initially to Seaport’s predecessor, PureTech Health in 2017, and now exclusively licensed to Seaport, Professor Porter and the MIPS team have worked closely with both PureTech and Seaport to progress the platform. A number of potential drug candidates are being developed using the platform including:

  1. SPT-300 (Formerly known as LYT-300) (Glyph Allopregnanolone) is being advanced into a Phase 2b study for major depressive disorder (MDD) with or without anxious distress. Allopregnanolone is a naturally occurring anti-stress molecule with clinically validated rapid antidepressant and anxiolytic activity, and SPT-300 retains this activity in an oral form.
  2. SPT-320 (Glyph Agomelatine) is being advanced into Phase 1 studies for the treatment of generalised anxiety disorder (GAD). SPT-320 uses Glyph to bypass liver first-pass metabolism and thus has the potential to lower the dose and reduce liver exposure while retaining efficacious systemic exposure of agomelatine that has been validated in multiple clinical studies in GAD.
  3. SPT-348 (Glyph Non-hallucinogenic Neuroplastogen), in development for the treatment of mood and other neuropsychiatric disorders, is being advanced into first-in-human enabling studies.

"It’s very rewarding to see the ongoing investment and support behind Seaport and the Glyph platform, which is showing great promise in its ability to advance much-needed and potentially life-changing neuropsychiatric medicines.” — Professor Christopher Porter

Website: www.seaporttx.com